Dr. Craig Kessler
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Tulane University School of Medicine (1973)
- Years since graduation
- 53
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 214
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1973Medical school: Tulane University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
DC license 12669
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Medstar Georgetown University Hospital Washington, DC
- Suburban Hospital Bethesda, MD
Medical groups
- Medstar Medical Group II LLC (3,767 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 214
- Services billed
- 1,085,522
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 200 | 124 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 30 | 24 |
| New patient office or other outpatient visit, 60-74 minutes | 28 | 28 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 25 | 25 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 21 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jakafi (ruxolitinib phosphate) | 85 |
| Pegasys (peginterferon alfa-2a) | 65 |
| Eliquis (apixaban) Other prescribers in Washington, DC | 63 |
| Tranexamic Acid | 38 |
| Besremi (ropeginterferon alfa-2b-njft) | 29 |
| Xarelto (rivaroxaban) Other prescribers in Washington, DC | 25 |
| Imatinib Mesylate | 24 |
| Promacta (eltrombopag olamine) | 24 |
| Enoxaparin Sodium Other prescribers in Washington, DC | 16 |
| Dabigatran Etexilate (dabigatran etexilate mesylate) Other prescribers in Washington, DC | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 34 payments worth $37,647 in total to this clinician.
| Pfizer Inc. | $12,600 |
|---|---|
| Novo Nordisk Inc | $11,235 |
| Octapharma USA, Inc. | $7,944 |
| Regeneron Pharmaceuticals, Inc. | $5,625 |
| Csl Behring | $48.47 |
| Genzyme Corporation | $35.59 |
| Exelixis Inc. | $34.38 |
| Daiichi Sankyo Inc. | $29.07 |
| Consulting Fee | $25,621 |
|---|---|
| Honoraria | $6,329 |
| Travel and Lodging | $5,054 |
| Food and Beverage | $643 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Oct 24, 2025 | Consulting Fee | $9,334 |
| Pfizer Inc. Oct 9, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $6,050 |
| Pfizer Inc. Mar 25, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $3,575 |
| Octapharma USA, Inc. Aug 21, 2025 | Honoraria | $2,329 |
| Octapharma USA, Inc. Jun 25, 2025 | Honoraria WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION | $2,000 |
| Octapharma USA, Inc. Dec 5, 2025 | Honoraria NUWIQ · COAGULATION | $2,000 |
| Regeneron Pharmaceuticals, Inc. Dec 5, 2025 | Consulting Fee | $1,854 |
| Pfizer Inc. Feb 28, 2025 | Travel and Lodging HYMPAVZI · IMMUNOLOGY · travel to New York, NY · in-kind | $1,632 |
| Regeneron Pharmaceuticals, Inc. Dec 5, 2025 | Consulting Fee | $1,159 |
| Pfizer Inc. Oct 9, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $1,100 |
All 24 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Travel and Lodging travel to WASHINGTON, DC · in-kind | $32.90 |
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Travel and Lodging travel to WASHINGTON, DC · in-kind | $29.82 |
| Octapharma USA, Inc. Dec 5, 2025 | Honoraria NUWIQ · COAGULATION | $2,000 |
| Regeneron Pharmaceuticals, Inc. Dec 5, 2025 | Consulting Fee | $1,854 |
| Regeneron Pharmaceuticals, Inc. Dec 5, 2025 | Consulting Fee | $1,159 |
| Regeneron Pharmaceuticals, Inc. Dec 5, 2025 | Consulting Fee | $927 |
| Regeneron Pharmaceuticals, Inc. Dec 5, 2025 | Consulting Fee | $927 |
| Regeneron Pharmaceuticals, Inc. Dec 5, 2025 | Consulting Fee | $695 |
| Octapharma USA, Inc. Dec 5, 2025 | Travel and Lodging NUWIQ · COAGULATION · travel to ORLANDO, FL | $299 |
| Novo Nordisk Inc Oct 24, 2025 | Consulting Fee | $9,334 |
| Novo Nordisk Inc Oct 24, 2025 | Travel and Lodging travel to Rosemont, IL · in-kind | $930 |
| Novo Nordisk Inc Oct 24, 2025 | Travel and Lodging travel to Rosemont, IL · in-kind | $367 |
| Novo Nordisk Inc Oct 24, 2025 | Travel and Lodging travel to Rosemont, IL · in-kind | $204 |
| Pfizer Inc. Oct 9, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $6,050 |
| Pfizer Inc. Oct 9, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $1,100 |
| Octapharma USA, Inc. Aug 21, 2025 | Honoraria | $2,329 |
| Octapharma USA, Inc. Jun 25, 2025 | Honoraria WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION | $2,000 |
| Octapharma USA, Inc. Jun 25, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to WASHINGTON, DC | $329 |
| Octapharma USA, Inc. Jun 25, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to WASHINGTON, DC | $329 |
| Octapharma USA, Inc. Jun 25, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to WASHINGTON, DC | $329 |
| Octapharma USA, Inc. Jun 25, 2025 | Travel and Lodging WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · COAGULATION · travel to WASHINGTON, DC | $329 |
| Pfizer Inc. Mar 25, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $3,575 |
| Pfizer Inc. Feb 28, 2025 | Travel and Lodging HYMPAVZI · IMMUNOLOGY · travel to New York, NY · in-kind | $1,632 |
| Pfizer Inc. Feb 28, 2025 | Travel and Lodging HYMPAVZI · IMMUNOLOGY · travel to New York, NY · in-kind | $243 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $120,959 in research payments for these studies, mostly to the institutions running them.
- NXT007 ROW Phase I II
Genentech, Inc. - Study name not reported
Diagnostica Stago, Inc - A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05568459 - BAY 949027, HEM-POWR Observational Study Evaluating Effectiveness and Safety of Real-World Treatment with Damoctocog alfa pegol in Previously Treated Patients with Hemophilia A
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.